0.001
0.00 (0.00%)
| Previous Close | 0.001 |
| Open | 0.001 |
| 52 Weeks Range |
| Operating Margin (TTM) | -550,895.36% |
| Diluted EPS (TTM) | -25.94 |
| Quarterly Revenue Growth (YOY) | -98.70% |
| Total Debt/Equity (MRQ) | 25.84% |
| Current Ratio (MRQ) | 0.080 |
| Operating Cash Flow (TTM) | -22.51 M |
| Levered Free Cash Flow (TTM) | -17.96 M |
| Return on Assets (TTM) | -46.32% |
| Return on Equity (TTM) | -204.37% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Aditxt, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.8 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | -2.5 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.40 |
Select this tab to load the latest available analysis.
|
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Institutions | 1.96% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |